Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/197298
Title: | Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53-Mutated Metastatic Colorectal Cancer |
Author: | Lahoz, Sara Rodríguez, Adela Fernández, Laia Gorría, Teresa Moreno, Reinaldo Esposito, Francis Oliveres, Helena Albiol, Santiago Saurí, Tamara Pesantez, David Riu Viladoms, Gisela Cuatrecasas Freixas, Miriam Jares Gerboles, Pedro Pedrosa, Leire Pineda, Estela Postigo, Antonio Castells Garangou, Antoni Prat Aparicio, Aleix Maurel Santasusana, Joan Camps, Jordi |
Keywords: | Càncer colorectal Metàstasi Medicina personalitzada Mutació (Biologia) Pronòstic mèdic Aprenentatge automàtic Colorectal cancer Metastasis Personalized medicine Mutation (Biology) Prognosis Machine learning |
Issue Date: | 30-Nov-2022 |
Publisher: | MDPI |
Abstract: | Next-generation sequencing (NGS) provides a molecular rationale to inform prognostic stratification and to guide personalized treatment in cancer patients. Here, we determined the prognostic and predictive value of actionable mutated genes in metastatic colorectal cancer (mCRC). Among a total of 294 mCRC tumors examined by targeted NGS, 200 of them derived from patients treated with first-line chemotherapy plus/minus monoclonal antibodies were included in prognostic analyses. Discriminative performance was assessed by time-dependent estimates of the area under the curve (AUC). The most recurrently mutated genes were TP53 (64%), KRAS or NRAS (49%), PIK3CA (15%), SMAD4 (14%), BRAF (13%), and FBXW7 (9.5%). Mutations in FBXW7 correlated with worse OS rates (p = 0.036; HR, 2.24) independently of clinical factors. Concurrent mutations in TP53 and FBXW7 were associated with increased risk of death (p = 0.02; HR, 3.31) as well as double-mutated TP53 and SMAD4 (p = 0.03; HR, 2.91). Analysis of the MSK-IMPACT mCRC cohort (N = 1095 patients) confirmed the same prognostic trend for the previously identified mutated genes. Addition of the mutational status of these genes upon clinical factors resulted in a time-dependent AUC of 87%. Gene set enrichment analysis revealed specific molecular pathways associated with SMAD4 and FBXW7 mutations in TP53-defficient tumors. Conclusively, SMAD4 and FBXW7 mutations in TP53-altered tumors were predictive of a negative prognostic outcome in mCRC patients treated with first-line regimens. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/cancers14235921 |
It is part of: | Cancers, 2022, vol. 14, num. 23, p. 5921 |
URI: | http://hdl.handle.net/2445/197298 |
Related resource: | https://doi.org/10.3390/cancers14235921 |
ISSN: | 2072-6694 |
Appears in Collections: | Articles publicats en revistes (Fonaments Clínics) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
729719.pdf | 2.27 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License